Novo Nordisk A/S, Krogshøjvej 49, Bagsværd, Denmark.
J Med Econ. 2009;12(4):281-90. doi: 10.3111/13696990903336597.
To assess the costs of severe hypoglycaemic events (SHEs) in diabetes patients in Germany, Spain and the UK.
Healthcare resource use was measured by surveying 639 patients aged ≥ 16 years, receiving insulin for type 1 (n=319) or type 2 diabetes (n=320), who experienced ≥ 1 SHE in the preceding year. Patients were grouped by location of SHE treatment: group 1, community (family/domestic); group 2, community (healthcare professional); group 3, hospital. Costs were calculated from published unit costs applied to estimated resource use. Costs per SHE were derived from patient numbers per subgroup. Weighted average costs were derived using a prevalence database.
Hospital treatment was a major cost in all countries. In Germany and Spain, costs per SHE for type 1 patients differed from those for type 2 patients in each group. Average SHE treatment costs were higher for patients with type 2 diabetes (Germany, €533; Spain, €691; UK, €537) than type 1 diabetes patients (€441, €577 and €236, respectively). Telephone calls, visits to doctors, blood glucose monitoring and patient education contributed substantially to costs for non-hospitalised patients.
Treatment of SHEs adds significantly to healthcare costs. Average costs were lower for type 1 than for insulin-treated type 2 diabetes, in all three countries.
评估德国、西班牙和英国糖尿病患者严重低血糖事件（SHEs）的成本。
通过调查 639 名年龄≥16 岁、正在接受 1 型（n=319）或 2 型（n=320）糖尿病胰岛素治疗且在前一年中经历≥1 次 SHE 的患者，衡量医疗资源的使用情况。根据 SHE 治疗地点将患者分为三组：组 1，社区（家庭/国内）；组 2，社区（医疗专业人员）；组 3，医院。根据公布的单位成本计算成本，应用于估计的资源使用情况。从每个亚组的患者数量中得出每次 SHE 的成本。使用患病率数据库得出加权平均成本。
在所有国家，医院治疗都是主要的成本。在德国和西班牙，1 型患者的每组 SHE 成本与 2 型患者的成本不同。2 型糖尿病患者（德国为 533 欧元，西班牙为 691 欧元，英国为 537 欧元）的平均 SHE 治疗成本高于 1 型糖尿病患者（分别为 441 欧元、577 欧元和 236 欧元）。对于未住院的患者，电话咨询、医生就诊、血糖监测和患者教育对成本有重大贡献。
SHE 治疗显著增加了医疗保健成本。在所有三个国家，1 型糖尿病的平均成本均低于胰岛素治疗的 2 型糖尿病。
